CATTRINI, CARLO
 Distribuzione geografica
Continente #
EU - Europa 3.491
AS - Asia 188
SA - Sud America 25
NA - Nord America 21
AF - Africa 3
Totale 3.728
Nazione #
IT - Italia 3.489
SG - Singapore 83
CN - Cina 53
VN - Vietnam 46
BR - Brasile 15
US - Stati Uniti d'America 15
AR - Argentina 6
MX - Messico 5
PE - Perù 2
PY - Paraguay 2
CA - Canada 1
DE - Germania 1
ID - Indonesia 1
IN - India 1
KW - Kuwait 1
LB - Libano 1
LT - Lituania 1
MA - Marocco 1
RE - Reunion 1
SY - Repubblica araba siriana 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 3.728
Città #
Genova 1.557
Genoa 1.280
Rapallo 337
Vado Ligure 312
Singapore 29
Beijing 16
Hanoi 13
Ho Chi Minh City 11
Ashburn 8
Mexico City 4
Biên Hòa 2
Bordighera 2
Can Tho 2
Tianjin 2
Buenos Aires 1
Bắc Ninh 1
Bến Cầu 1
Cao Lanh 1
Catamarca 1
Chalco 1
Cidade Ocidental 1
Ciudad del Este 1
Curitiba 1
Divinópolis 1
Durban 1
Embu das Artes 1
Guangzhou 1
Guarulhos 1
Haiphong 1
Honolulu 1
Hải Dương 1
Iguape 1
Jakarta 1
Kuwait City 1
La Plata 1
Lima 1
Long An 1
Los Angeles 1
Macaé 1
Milan 1
Montreal 1
Mumbai 1
Nantong 1
New York 1
Ninh Bình 1
Nova Iguaçu 1
Nuremberg 1
Phủ Lý 1
Porto Alegre 1
Quảng Ngãi 1
Quận Bình Thạnh 1
Quận Ninh Kiều 1
Registro 1
Rio das Ostras 1
Saint-Leu 1
San Jose 1
San Lorenzo 1
Santa Fe 1
Santiago de Surco 1
Shanghai 1
Sumaré 1
Tashkent 1
Thái Nguyên 1
Tây Ninh 1
Tétouan 1
Uberlândia 1
Villa José León Suárez 1
Vilnius 1
Volta Redonda 1
Vĩnh Long 1
Vĩnh Tường 1
Wuhan 1
Totale 3.633
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 232
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 187
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 177
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 173
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 170
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 169
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 161
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 158
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 153
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 150
Bone metastases from prostate cancer: hormonal therapy 145
Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives 144
Immunotherapy for genitourinary cancer: State of the art and new perspectives 140
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 134
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 128
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 126
To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone 121
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes 120
Lipidomic profiling in patients with metastatic castration-resistant prostate cancer (mCRPC) 117
Atezolizumab and bladder cancer: facing a complex disease 111
EFFICACY AND SAFETY OF SUNITINIB AND EVEROLIMUS AS FRONTLINE TREATMENT FOR NON-CC-RCC: A POOLED-ANALYSIS FROM RANDOMIZED TRIALS 110
Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience 110
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study 98
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 97
Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer 90
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer 90
Combination therapy in metastatic renal cell carcinoma: Back to the future? 87
Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States 77
Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty? 44
null 40
Totale 3.859
Categoria #
all - tutte 13.406
article - articoli 12.641
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 446
Totale 26.493


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021190 0 0 0 0 0 32 6 32 18 50 23 29
2021/2022344 15 10 16 30 16 40 7 85 25 35 25 40
2022/2023388 28 47 3 37 79 55 0 30 50 7 47 5
2023/2024306 10 63 8 43 10 55 12 8 10 16 11 60
2024/2025830 30 47 26 72 88 75 94 176 16 34 89 83
2025/2026661 169 18 185 80 190 19 0 0 0 0 0 0
Totale 3.859